NIH study identifies experimental opioid with strong pain relief and lower addiction risk

The study focuses on DFNZ, a molecule derived from a class of synthetic opioids first explored in the mid-20th century but largely abandoned due to their high potency. This research revisits nitazenes using modern pharmacological tools and aims to redesign them for greater safety. Investigators say the results represent unexpected…

Read Entire Article